… growth factor/vascular permeability factor (… therapy. In several animal models, neutralizing
anti-VEGF/VPF antibodies have shown encouraging inhibitory effects on solid tumor growth, …

… One of the most interesting targets in this setting is transforming growth factor β (TGF-β).
TGF-β can promote tumor growth, invasion and metastasis. However, TGF-β also has a …

… Vascular endothelial growth factor (VEGF) is the major inducer of angiogenesis and … of
VEGF in the anti-tumor immune response. In addition, we summarize therapeutic strategies based …

… of an anti-tumor angiogenesis strategy in the field of cancer treatment. Tumor angiogenesis
is induced by angiogenic growth factors including vascular endothelial growth factor (VEGF), …

… -angiogenic therapeutic agent based on an engineered variant of the tenth type III domain
of human fibronectin, ie, an AdnectinTM, designed to inhibit vascular endothelial growth factor …

… , confirm that these compounds achieve the desired anti-tumor activity by inhibiting
farnesyl-protein transferase. Unlike cytotoxic anti-tumor agents, FTIs appear to act without overt …

… in tumor growth and anti-tumor therapy. Membrane attack complex (MAC) and anti-tumor …
, such as upregulation of oncogenic growth factors, activation of mitogenic signaling pathways …

… and enhance tumor growth by secreting growth factors such as transforming growth factor β
(… corneal neovascularization but may be used in anti-tumor therapy as well; transfection with …

… Thus, because infliximab showed stronger anti-tumor properties than etanercept in our in
vivo … Effect of inflammatory cytokines and growth factors on tumour cell adhesion to the …

… anti-tumor therapies in both subcutaneous and orthotopic pancreatic tumors [205]. Significant
signal enhancement of tumor vasculature was observed when compared with untargeted …